Muscle-Invasive Bladder Cancer Treatment Practices

Opinion
Video

Karine Tawagi, MD, and Sia Daneshmand, MD, offer comprehensive insights on treatment practices for patients with muscle-invasive bladder cancer.

Recent Videos
Immunotherapy-based combinations may elicit a synergistic effect that surpasses monotherapy outcomes among patients with muscle-invasive bladder cancer.
Considering which non–muscle-invasive bladder cancer cases may be cured by surgery alone may help mitigate overtreatment in this patient group.
Event-free survival benefit was observed among BCG-naïve patients with carcinoma in situ undergoing treatment with sasanlimab plus BCG.
Comprehensive prehabilitation may help prepare patients for bladder-preserving surgery, helping to optimize quality of life outcomes.
Ongoing research suggests environmental exposures and the role of microbiomes may influence bladder cancer development and response to treatment.
Related Content
Results from the KEYNOTE-905 trial led to the approval of pembrolizumab/enfortumab vedotin in muscle invasive bladder cancer.

FDA OKs Pembrolizumab/Enfortumab Vedotin in Muscle Invasive Bladder Cancer

Ariana Pelosci
November 21st 2025
Article

Results from the KEYNOTE-905 trial led to the approval of pembrolizumab/enfortumab vedotin in muscle invasive bladder cancer.

Prospective data observed with the gemcitabine intravesical system may be superior to prior reports of other therapies in BCG-unresponsive NMIBC.

Gemcitabine Intravesical System Offers Tremendous Benefits in NMIBC

Gary Steinberg, MD
September 29th 2025
Podcast

Prospective data observed with the gemcitabine intravesical system may be superior to prior reports of other therapies in BCG-unresponsive NMIBC.

The FDA agreed that data from the UTOPIA trial, with UGN-103 demonstrating a 77.8% 3-month CR rate in patients with LG-IR-NMIBC, support an NDA submission.

UGN-103 Exhibits Durable Responses in Recurrent LG-IR-NMIBC

Roman Fabbricatore
November 6th 2025
Article

The FDA agreed that data from the UTOPIA trial, with UGN-103 demonstrating a 77.8% 3-month CR rate in patients with LG-IR-NMIBC, support an NDA submission.

Navigating the Evolving Second-Line Landscape of Metastatic Urothelial Carcinoma

Navigating the Evolving Second-Line Landscape of Metastatic Urothelial Carcinoma

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
August 14th 2025
Podcast

The latest in first- and second-line therapies for bladder cancer, including trial data, AE management, and the role of molecular testing, were discussed in the latest Oncology Decoded podcast.

Enfortumab vedotin plus pembrolizumab before and after surgery improved EFS vs surgery alone in patients with MIBC in the phase 3 EV-303 trial.

FDA Grants Priority Review to Enfortumab Vedotin Combo in MIBC Subset

Tim Cortese
October 22nd 2025
Article

Enfortumab vedotin plus pembrolizumab before and after surgery improved EFS vs surgery alone in patients with MIBC in the phase 3 EV-303 trial.

Updated results from SunRISe-4 support further investigation of the gemcitabine intravesical system plus cetrelimab in MIBC.

Gemcitabine Intravesical System Combo Shows High pCR Rate in MIBC

Kristi Rosa
October 17th 2025
Article

Updated results from SunRISe-4 support further investigation of the gemcitabine intravesical system plus cetrelimab in MIBC.